PIAR
Redefining Infection Control through Engineered Therapeutic Peptides
Primary Users
Pharmaceutical companies, biotechnology startups developing antimicrobial therapies and biomedical researchers.
End Users
Healthcare professionals and patients affected by antibiotic-resistant infections.
Other Stakeholders/Collaborators
Government, public health organisations, drug development agencies, and research funding bodies focused on global health innovation.
Peptide Innovation for Antimicrobial Resistance
Our project pioneers a new generation of antimicrobial peptides that destroy pathogens by targeting their cell membranes, providing a powerful and sustainable alternative to conventional antibiotics.
Antimicrobial resistance (AMR) poses one of the greatest global health threats of the 21st century. The excessive use of antibiotics and the natural ability of microbes to evolve resistance mechanisms have rendered many existing drugs ineffective. This results in prolonged illnesses, higher mortality rates, and increased healthcare costs. There is a critical need for novel antimicrobial agents that remain effective against resistant pathogens without accelerating resistance development.
How PIAR Can Help The Current Situation.
Our Value Proposition.
The PIAR project develops modified therapeutic peptides that kill microbes through membrane disruption—a mechanism that limits the development of resistance. By enhancing peptide stability and bioavailability using enzymatic macrocyclization and chemical modifications, these engineered peptides retain broad-spectrum activity against multidrug-resistant bacteria. This approach bridges the gap between natural peptide efficiency and clinical applicability, providing a durable antimicrobial solution.
PIAR Team
Get in touch.
We would love your feedback on our potential technology, whatever your background or interest in our project is. Your input will help us shape the offering to provide something that best meets the need of the market.
